Chuanning Biology first-half net profit 278 million yuan, synthetic biology revenue up 221%
Chuanning Biology disclosed its 2026 semi-annual report. In the first half of the year, it achieved total operating revenue of 2.098 billion yuan and net profit attributable to shareholders of the listed company of 278 million yuan. Second-quarter net profit was 167 million yuan, roughly flat compared with the same period last year and steadily higher than the first quarter. The company's synthetic biology production base in Gongliu County, Xinjiang, achieved operating revenue of 71.7599 million yuan in the first half, up 221.38% year on year. High-value-added products such as bisabolol, ergothioneine and squalane have already reached large-scale production. Domestic approval of ergothioneine as a new food ingredient has entered a critical stage and is expected to be formally approved in the second half of 2026.
Cathay Biotech first-half net profit 372 million yuan, up 20.75% year on year
Cathay Biotech disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.9 billion yuan, up 13.73% year on year, and net profit attributable to shareholders of the listed company of 372 million yuan, up 20.75% year on year. The profit growth was mainly driven by continued volume expansion of long-chain dibasic acids and revenue contribution from new product sales. During the reporting period, bio-based sebacic acid and bio-based piperidine continued to be introduced to the market, bio-based azelaic acid entered the customer sampling stage, and long-chain polyamide modified products achieved large-scale sales. The company also led an investment in and increased its stake in the AI protein design company MoleculeMind, and currently holds about 17.43% of its shares, making it the largest external shareholder. At the same time, its self-built high-throughput research and development platform has entered the commissioning stage.
▲
Cibus pushes Latin America rice launch to 2028, sees $20M-$40M biofragrance opportunity
Cibus updated its Latin America rice launch timing to 2028 while outlining a potential $20 million to $40 million annual revenue opportunity from biofragrance partnerships. CEO Craig Wichner, on his first earnings call, emphasized scaling revenue and capital discipline, while CFO Carlo Broos reported cash and equivalents of $20.4 million as of June 30, 2026, sufficient into early Q1 2027. Q2 revenue was $1 million, with six-month revenue up 35% to $2.7 million, and net loss was $22.1 million, or $0.29 per share. Management expects royalties to start flowing in 2028 and build through 2029, and reiterated expectations for additional biofragrance scale-up orders in the second half of 2026.
Illumina Inc
Thermo Fisher Scientific Inc
Ginkgo Bioworks Holdings
International Business Machines
Microsoft Corporation